Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHIKV VLP Vaccine for Prevention of Chikungunya Disease in Adolescents and Adults
NCT07467707Phase 3Recruiting
- Sponsor
- Bavarian Nordic
- Start
- May 2026
- Primary completion
- May 2030
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 3 trial of CHIKV VLP vaccine in Chikungunya (CHIKV), sponsored by Bavarian Nordic. Started May 2026; status: recruiting.
02
Drugs
CHIKV VLP vaccine
03
Conditions
Chikungunya (CHIKV)
Beyond the preview
Go deeper on NCT07467707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07467707.